Adverse Effects of HMG CoA Reductase Inhibitor and Garlic on Renal Function in Patients with Diabetic Dyslipidemia

被引:0
|
作者
Siddiqui, Naveed Ali [1 ]
Ishaque, Imran [2 ]
Rahat, Yousra [3 ]
Akhtar, Naheed [4 ]
Tehreem, Umaya [3 ]
Javed, Rafia [3 ]
Ali, Rayyan [3 ]
机构
[1] United Med & Dent Coll, Dept Biochem, Karachi, Pakistan
[2] United Med & Dent Coll, Dept Anat, Karachi, Pakistan
[3] United Med & Dent Coll, Karachi, Pakistan
[4] Karachi Inst Med Sceinces, Dept Anat, Karachi, Pakistan
来源
ANNALS ABBASI SHAHEED HOSPITAL & KARACHI MEDICAL & DENTAL COLLEGE | 2021年 / 26卷 / 02期
关键词
Urea; Creatinine; Diabetic dyslipidemia; HMG-CoA reductase inhibitor; Coronary heart disease; CARDIOVASCULAR-DISEASE; FAILURE SECONDARY; LIPID PROFILE; RHABDOMYOLYSIS; SIMVASTATIN;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: To analyze the adverse effects of HMG CoA reductase inhibitor (statin) and garlic (Allium sativum) on renal function in diabetic dyslipidemic patients. Methods: This clinical trial was conducted at Surgeon Munawar Memorial Hospital, Karachi from 1st March 2019 to 30th August 2019. Total of 60 patients of 30-70 years of age with abnormal lipid profile were enrolled for this study after a written consent. The study was conducted to assess the side effects of statin (20 mg/day) and garlic (300 mg/day) in diabetic dyslipidemia patients. The study period consisted of six months. Blood pressure, body weight and height of subjects were assessed. The patient answered the questionnaire on health complaints, smoking, social role, drug usage, family history and dietary pattern. The initial inclusion criteria of the patient were 1) Age between 30-70 years old of either sex, 2) Patients with diabetic dyslipidemia. The exclusion criteria were 1) Pregnancy or lactation, 2) Patients with liver diseases, 3) Patients with renal diseases. Detailed medical history and physical examination of all patients were carried out. Results: This study included 60 patients with an abnormal lipid profile of age 30-70 years. International statin product (20 mg/day) and local garlic product (300 mg/day) for 08 weeks were used for oral administration in patients. Urea and creatinine levels in the serum of diabetic dyslipidemic patients were measured before and after treatment with an international statin (20 mg/day) and a local garlic product (300 mg/day). Conclusion: According to the findings of this study, statins increase the serum level of urea and creatinine while has no effect on urea and creatinine serum level.
引用
收藏
页码:71 / 75
页数:5
相关论文
共 50 条
  • [21] In vitro and in vivo antiproliferative effects of simvastatin, an HMG-CoA reductase inhibitor, on human glioma cells
    Kikuchi, T
    Nagata, Y
    Abe, T
    JOURNAL OF NEURO-ONCOLOGY, 1997, 34 (03) : 233 - 239
  • [22] In vitro and in vivo antiproliferative effects of simvastatin, an HMG-CoA reductase inhibitor, on human glioma cells
    Tetsuro Kikuchi
    Yasufumi Nagata
    Toshiaki Abe
    Journal of Neuro-Oncology, 1997, 34 : 233 - 239
  • [23] NK-104: a novel synthetic HMG-CoA reductase inhibitor
    Kajinami, K
    Mabuchi, H
    Saito, Y
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2000, 9 (11) : 2653 - 2661
  • [24] Dyslipidemias and HMG-CoA reductase inhibitor prescription in heart transplant recipients
    de Denus, S
    Al-Jazairi, A
    Loh, E
    Jessup, M
    Stanek, EJ
    Spinler, SA
    ANNALS OF PHARMACOTHERAPY, 2004, 38 (7-8) : 1136 - 1141
  • [25] Synthesis and characterization of Rosuvastatin calcium impurity A; a HMG-CoA reductase inhibitor
    Lee, Young Hee
    Viji, Mayavan
    Lee, Eunhwa
    Jo, Hyeju
    Yoo, Kyung
    Sim, Jaeuk
    Lee, Sunhwan
    Lee, Kiho
    Lee, Heesoon
    Jung, Jae-Kyung
    TETRAHEDRON LETTERS, 2017, 58 (26) : 2614 - 2617
  • [26] Renal hemodynamic effects of the HMG-CoA reductase inhibitors in autosomal dominant polycystic kidney disease
    Zand, Ladan
    Torres, Vicente E.
    Larson, Timothy S.
    King, Bernard F.
    Sethi, Sanjeev
    Bergstralh, Eric J.
    Angioi, Andrea
    Fervenza, Fernando C.
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2016, 31 (08) : 1290 - 1295
  • [27] HMG CoA reductase-inhibitor-related myopathy and the influence of drug interactions
    Huynh, T
    Cordato, D
    Yang, F
    Choy, T
    Johnstone, K
    Bagnall, F
    Hitchens, N
    Dunn, R
    INTERNAL MEDICINE JOURNAL, 2002, 32 (9-10) : 486 - 490
  • [28] Shoulder stiffness: A common adverse effect of HMG-CoA reductase inhibitors in women?
    Harada, K
    Tsuruoka, S
    Fujimura, A
    INTERNAL MEDICINE, 2001, 40 (08) : 817 - 818
  • [29] Comparison of the antiatherosclerotic effects of dihydropyridine calcium channel blocker and HMG-CoA reductase inhibitor on hypercholesterolemic rabbits
    Takayama, Makoto
    Matsubara, Masahiro
    Arakawa, Emi
    Takada, Chie
    Ina, Yasuhiro
    Hasegawa, Kazuhide
    Yao, Kozo
    VASCULAR PHARMACOLOGY, 2007, 46 (04) : 302 - 308
  • [30] Effects of HMG-CoA Reductase Inhibitors on Coagulation and Fibrinolysis Processes
    Robert Krysiak
    Boguslaw Okopień
    Zbigniew S. Herman
    Drugs, 2003, 63 : 1821 - 1854